Cara Therapeutics

$19.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.56 (-2.83%) Today
$0.00 (0.00%) As of 1:00 PM UTC after-hours

Why Robinhood?

You can buy or sell CARA and other stocks, options, and ETFs commission-free!

About CARA

Cara Therapeutics, Inc. Common Stock, also called Cara Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT. The listed name for CARA is Cara Therapeutics, Inc. Common Stock.

CEO
Derek T. Chalmers
Employees
67
Headquarters
Stamford, Connecticut
Founded
2004
Market Cap
953.47M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
700.45K
High Today
$19.91
Low Today
$18.83
Open Price
$19.33
Volume
389.24K
52 Week High
$22.60
52 Week Low
$8.88

CARA News

BenzingaFeb 24

Preview: Cara Therapeutics's Earnings

On Thursday, February 25, Cara Therapeutics (NASDAQ:CARA) will release its latest earnings report. Decipher the announcement with Benzinga's help. What Are Ear

CARA Earnings

-$0.74
$0.04
$0.81
$1.59
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$0.36 per share
Actual
$1.59 per share
Replay Earnings Call

You May Also Like

STCN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure